Navigation Links
Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Date:11/15/2007

ion that may slow the onset of future bacterial resistance. In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication.

About John Bartlett, M.D.

Dr. Bartlett is a Professor of Medicine in the Division of Infectious Diseases at The Johns Hopkins University School of Medicine, Baltimore, Maryland. He received his undergraduate degree at Dartmouth in 1959 and his medical degree at Upstate Medical Center in Syracuse in 1963. His training in internal medicine was done at the Brigham Hospital in Boston and the University of Alabama, after which he received his fellowship training in infectious diseases at UCLA. In 1970, he joined the faculty of UCLA, and then joined the faculty of Tufts University School of Medicine where he served as Associate Chief of Staff for Research at the Boston VA Hospital. In 1980, he moved to Hopkins where he served as Chief of the Infectious Diseases Division at the School for 26 years, stepping down in June of 2006.

Dr. Bartlett is a past president of the Infectious Disease Society of America (IDSA) and an author of the IDSA/ATS Consensus Guidelines on the Management of Community-Acquired Pneumonia. He was an author of "Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America," which was published in Clinical Infectious Diseases in 2006. He has authored over 500 articles and reviews in peer-reviewed journals, more than 280 book chapters, and 67 editions of 18 books. He has also served on editorial boards for 19 medical journals including Infectious Diseases in Clinical Practice (Editor) and Clinical Infectious Diseases Medicine (Associate Editor).

About Donald
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
4. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
6. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...n January 2009 and Final Trial ...t. 13 /- Neurobiological,Te...nnounced that following a,meeting with the U.S. Fo...(TM) (ancrod) Phase 3 clinical program for acute i...nd analyze data from its two concurrently,running ...
(Date:10/13/2008)... Facet Solutions, Inc. today,announced the complet...S,IDE Pilot Study. The results show a 78% reductio...n 80% reduction in Visual Analog Scores (VAS) for,... for Facet Solutions,added, "We are very pleased ...demonstrate significant pain relief but the safety...
(Date:10/12/2008)...signed for more uniform drug ..., Oct. 12 /- Boston,Scienti...rehensive data from,the TAXUS ATLAS clinical progr... single-arm, historically controlled trials, which...ng Stent System in a variety of,lesions and patien...
(Date:10/10/2008)...0 /-,XTENT, Inc. (Nasdaq: ...ng-term follow-up data from the CUSTOM I, II and I... Research Foundation,s (CRF) twentieth annual,Tran...g in Washington, DC.,The CUSTOM clinical trials ar...safety and efficacy of the Custom NX(R) drug eluti...
Breaking Medicine Technology:Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 2Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 3Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 2Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 3Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 4Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 5Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent 6XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week 2Eklin Medical Reports Record Revenues for 2007 3303 1Eklin Medical Reports Record Revenues for 2007 3303 2Eklin Medical Reports Record Revenues for 2007 3303 3Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 1Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 2Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 3Hayes Clinical Labs to Market MedeFiles Proprietary Electronic Medical Record Management Solution to Patients 3301 4Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th 11903 1Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th 11903 2Centene Foundation for Quality Healthcare Awards Grant to Texas Parent to Parent 11901 1Centene Foundation for Quality Healthcare Awards Grant to Texas Parent to Parent 11901 2Centene Foundation for Quality Healthcare Awards Grant to Texas Parent to Parent 11901 3
...Analysis Shows Statistically Significant Changes i...alif., March 26, 2007 /PRNewswire-FirstCall/ --,Al...e initial,results from its Phase IIa clinical tria...c patients with acute agitation. The 10 mg,dose of...rial,which was a statistically-significant reduct...
...d CAPTURE 2 Findings Suggest Improved Outcomes in ...26, 2007 /PRNewswire-FirstCall/ --,Positive 30-day...tid stenting can be performed with positive result...ience in real-world,(non-clinical trial) settings ...urgery. Interim results from the first 1,500,patie...
Other Medicine Technology:Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 2Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 3Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 4Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 5Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 6Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 2Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 3Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 4
(Date:10/13/2008)...ges Latinos to Get Tested, LOS ANGELES, Oct. 13 /...half of all newly diagnosed HIV/AIDS cases,reporte...ionally., -- A week of activities aimed at raisin...ting to coincide with National Latino AIDS Awarene...r Community, Our Responsibility: Latinos in Action...
(Date:10/13/2008)...n ever before, study finds , , MONDAY,...ver are being treated for high blood pressure, say...nd Blood Institute. , The major factor in the d...igh blood pressure appears to be the obesity epide...dditional efforts are needed to prevent hypertensi...
(Date:10/13/2008)...g advances study Study needed because of low... 13 /PRNewswire/ -- Advanced Circulatory Systems, ...ced today that it has received,an additional $1.5 ...,Health (NIH) to continue a study testing two devi...rdiac arrest outside a hospital. Parts of Oakland,...
(Date:10/13/2008)...valve.com ) announced today that the expanded clin...aneous aortic valve replacement (PAVR) in high-ris...l patients at an accelerating pace. More than 1,80...ly 100 centers in 20 countries. , ...er 13, 2008 -- During the Monday Transcatheter Ao...
Breaking Medicine News(10 mins):Health News:Nearly Half of Newly Diagnosed HIV/AIDS Cases in Los Angeles County Are Among Latinos 2Health News:Blood Pressure on the Rise in America 2Health News:Blood Pressure on the Rise in America 3Health News:3 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Health News: CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) : Highly encouraging registry data also presented at TCT 2008 2
...ofi-Aventis, one of the world's leading pharmaceut... Taxotere (docetaxel) improves survival in patient... clinical trial named TAX 327 compared Taxotere pl...one) plus prednisone. The study included a little ...
...nagers who use mobile phones for many hours a day ...ay develop psychological disorders, says a study t...s. // Francisca Lopez Torrecillas, a lecturer at t...chological assessment and treatment of the Univers...
...ian belief and knowledge are great healers and 140...rently in Delhi to study this value system. // "Th...tal role in dealing with mental health issues and ...re about it," said Patrick Bantman, a psychiatrist...
...en aiming to shed after-pregnancy pounds should ad...cording to a new study by Harvard researchers. // ...isk for weight gain in women,” said lead author Em...n that early postpartum period — such as diet, tel...
Other Medicine News:Health News:Mobile Phone Addiction may Cause Psychological Problems 2Health News:Simple Solutions to Postpartum Weight Retention 2
Spinal Concepts has developed a versatile set of instruments intended to make posterior lumbar interbody fusion procedures precise, simple and quick every time. The Harmony PLIF Instrument Set is the
Kerrison (Spurling) Laminectomy Rongeur. 15 cm - 6, thick footplate, large handle, 90 up-cutting, 2 mm wide.
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide.
OSV II Smart ValveTM, Hakim, H-V Lumbar Valve system is the intelligent choice for meeting the complex demands of hydrocephalus shunting. Automatic pressure response causes the valve to adjust automa
Medicine Products: